Decorative dot pattern background image.
Decorative blue shape background image. Decorative blue shape background image. Decorative blue shape background image. Decorative blue shape background image.

Henlius HLX10-020-SCLC302

Trial Overview

Official Title

Randomized, Double-Blind, International Multicenter, Phase III Study to Evaluate the Anti-Tumor Efficacy and Safety of HLX10 (Recombinant Humanized Anti-PD-1 Monoclonal Antibody) or Placebo in Combination with Chemotherapy (Carboplatin/Cisplatin-Etoposide) and Concurrent Radiotherapy in Patients with Limited-Stage Small Cell Lung Cancer (LS-SCLC)

Study Purpose

To evaluate the effectiveness of HLX10 in combination with chemotherapy and radiation. 

 

Diagnosis

Limited stage small cell lung cancer (LS-SCLC)

Eligibility

Unresectable stage I-III patients able to be safely treated with curative radiation. 

 

Intervention

Experimental arm: HLX10 plus chemotherapy (carboplatin or cisplatin and etoposite) plus radiation

Control arm: placebo plus chemotherapy (carboplatin or cisplatin and etoposite) plus radiation

For more information, click the link below:

 

https://clinicaltrials.gov/study/NCT05353257?term=HLX10-020-SCLC302&rank=1

 

Key Participation Requirements
Trial Location(s)
Methodist Estabrook Cancer Center
Gender
Male or Female
Age
18 years and Older
Enrollment Status
Pending
Phase
Phase III